tbuckley/cabot-search huggingface dataset:
In adults ≥ 70 years of age, an adjuvanted herpes zoster subunit vaccine reduced herpes zoster at a mean 3.7 years
Authors: Henry S. Sacks
Journal: Annals of Internal Medicine (2017)

ACP Journal Club17 January 2017In adults ≥ 70 years of age, an adjuvanted herpes zoster subunit vaccine reduced herpes zoster at a mean 3.7 yearsHenry S. Sacks, PhD, MDHenry S. Sacks, PhD, MDIcahn School of Medicine at Mount Sinai, New York, New York, USA (H.S.S.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/ACPJC-2017-166-2-005 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationCunningham AL, Lal H, Kovac M, et al; ZOE-70 Study Group. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375:1019-32. https://pubmed.ncbi.nlm.nih.gov/27626517Clinical Impact RatingsGIM/FP/GP: Geriatrics: Infectious Disease: References1 Shingles: a belt of roses from hell. Br Med J. 1979;1:5. [PMID: 216456] Google Scholar2 McLaughlin JM, McGinnis JJ, Tan L, Mercatante A, Fortuna J. Estimated human and economic burden of four major adult vaccine-preventable diseases in the United States, 2013. J Prim Prev. 2015;36:259-73. [PMID: 26032932] Google Scholar3 Schmader K. Herpes zoster in older adults. Clin Infect Dis. 2001;32:1481-6. [PMID: 11317250] Google Scholar4 Oxman MN, Levin MJ, Johnson GR, et al; Shingles Prevention Study Group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352:2271-84. [PMID: 15930418] Google Scholar5 Williams WW, Lu PJ, O’Halloran A, et al; Centers for Disease Control and Prevention (CDC). Surveillance of vaccination coverage among adult populations—United States, 2014. MMWR Surveill Summ. 2016;65:1-36. [PMID: 26844596] Google Scholar Author, Article, and Disclosure InformationAffiliations: Icahn School of Medicine at Mount Sinai, New York, New York, USA (H.S.S.)This article was published at Annals.org on 3 January 2017. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byHerpes Zoster in the Older Adult 17 January 2017Volume 166, Issue 2Page: JC5KeywordsElderlyImmunosuppressivesInfectious diseasesMorbidityMotor vehicle crashesRashesSafetySaline solutionsShinglesVaccines ePublished: 17 January 2017 Issue Published: 17 January 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Toward a Healthier Patient Voice
Authors: Ray Moynihan, Lisa Bero
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Primary Allogeneic T-Cell Responses Against In Vitro Modified Mantle Cell Lymphoma (MCL) Cells: Implications for Adoptive Immunotherapy after HLA-Matched Stem Cell Transplantation (SCT).
Authors: M. Hoogendoorn, J. Olde Wolbers, W. M. Smit, I. Jedema, M. R. Schaafsma, R. M.Y. Barge, R. Willemze, J. H.F. Falkenburg
Journal: Blood (2004)
Qualitative Assessment Of Symptoms and Functional Impact In Relapsed/Refractory Multiple Myeloma Patients and Comparison To The EORTC QLQ-C30 and My-20, FACT-MM, and MDASI-MM
Authors: Peter C Trask, Fiona Taylor, Alan Shields, Meghan Gallagher, Jyotsna Mehta, Catherine Foley, Funke Olude, Roger Lamoureux, Ramon Iovin, Karl Hsu
Journal: Blood (2013)
Differente Patterns of Telomerase Reverse Transcriptase (hTERT) mRNA Variant Expression Profiles in Patients with Myelodysplastic Syndromes (MDS) and Acute Myelogenous Leukemia (AML)
Authors: Evgenia Verrou, Vassiliki Kaloutsi, Eirini Katodritou, Vasilia Garypidou, Anna Nikitidou, Vassiliki Gastari, Anna Lazaridou, Konstantinos Zervas, Vassiliki Kotoula
Journal: Blood (2008)
In Vivo Chemotherapy Protection and Efficacy of Multidrug Resistance (MDR-1) Gene Transfer in a Patient with Refractory Non-Hodgkin’s Lymphoma (NHL).
Authors: Pamela S. Becker, Adrianne N. Hanks, Ying Ping Yu, Ann Marie Ceredona, William V. Walsh, Judith L. O’Donnell, Christopher Baum, Lynn Kallander, Philip A. Lowry, T.J. Fitzgerald, Peter Westervelt, F. Marc Stewart
Journal: Blood (2005)
Abstract 133: Assessment of Therapeutic Effect of Medium-Dose Intravenous Immunoglobulin as An Initial Treatment for Kawasaki Disease in Korean Children
Authors: Hye-Jin Kim, Jae Young Lee, Sun Hee Shim, Eun-Jung Lee, Jin Hee Oh, Ji Whan Han, Kyung Yil Lee, Soon Ju Lee
Journal: Circulation (2015)

Objectives: A high-dose (2g/kg) intravenous immunoglobulin (IVIG) has been generally incorporated into the acute treatment protocols for Kawasaki disease (KD), with ongoing debates on this issue. The aim of this study was to assess the effectiveness of medium-dose (1g/kg) IVIG as an initial treatment of KD in Korean children. Methods: A retrospective study was done in a total of 255 children with KD, in whom 91 patients (group 1, mean age; 2.8 ± 2.5 years) had 2g/kg of IVIG and 164 patients (group 2, mean age; 2.7 ± 1.7 years) had 1g/kg of IVIG as an initial treatment of KD, along with 30-50 mg/kg of aspirin. Echocardiography (Echo) was done during admission, around 2 weeks, 2 months, and 1 year after the onset of fever according to our protocol. Patients who completed one-year Echo study were included in this study. Patients’ demographic, laboratory, and Echo findings were recorded, and compared between groups. Coronary artery lesions (CAL) were defined as a coronary artery diameter &gt; 2 SD of normal mean for age or coronary artery stenosis. The primary end point was the incidence of CAL at 1 year after treatment. The secondary end points were the incidence of CAL at 2 weeks and 2 months study, and clinical outcomes. Comparisons between groups were done using an unpaired t-test or Fisher’s exact test. Results: There was no significant difference in age, gender, and laboratory findings before treatment between the two groups. Group 1 had higher incidence of CAL at 2 weeks (32/91, 35.2 % vs. 33/164, 20.2 %, p = 0.011), but similar incidence of CAL at 2 months (18/91, 19.8% vs. 24/164, 14.6%, p &gt; 0.05) and 1 year (6/91, 6.6% vs. 10/164, 6.1%, p &gt; 0.05) compared with group 2. Group 1 had a higher proportion of patients needed additional dose of IVIG (23/91, 25.3% vs. 15/164, 9.1%, p = 0.001), but received significantly lower total dose of IVIG (1.3 ± 0.7 g/kg vs. 2.1 ± 0.5 g/kg, p &lt; 0.001) compared with group 2. There was no difference in duration of fever after IVIG and duration of hospital stay between the two groups. Conclusion: This study demonstrated that medium-dose IVIG is as effective as high-dose IVIG for the treatment of KD in terms of CAL prevention, defervescence, and duration of hospital stay. Further prospective and randomized study is needed to verify this.
Activity of Circulating Proteasomes Correlates with Clinical Behavior in Patients with Chronic Myeloid Leukemia.
Authors: Wanlong Ma, Hagop Kantarjian, Amber Donahue, Xi Zhang, Susan O’Brien, Iman Jilani, Elihu Estey, Zeev Estrov, Jorge Cortes, Michael Keating, Francis Giles, Maher Albitar
Journal: Blood (2007)
Alemtuzumab Administered by Subcutaneous Route Is Less Effective Than Intravenous Route for First Line Therapy of T-Cell Prolymphocytic Leukaemia: Results of a Pilot Study (UKCLL05)
Authors: Ami t S Khot, Estella Matutes, Pawel A Kaczmarek, Mike Hamblin, Ashok Roy, Effie Grand, Mark E Ethell, Claire E Dearden
Journal: Blood (2008)
The Influence of Adding Low-Dose (400cGy) Total Body Irradiation (TBI) on Outcomes of Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukaemia (AML) with Myeloablative Conditioning Incorporating Daily Intravenous Busulfan, Fludarabine and Low-Dose Antithymocyte Globulin.
Authors: Mary Lynn Savoie, Alexander Balogh, M. Ahsan Chaudhry, Oluyemi Jeje, Douglas A. Stewart, Nizar J. Bahlis, Jan Storek, Christopher B. Brown, Diana M. Quinlan, A. Robert Turner, Loree M. Larratt, James A. Russell
Journal: Blood (2005)
Design and Validation of the GI-NEC Score to Prognosticate Overall Survival in Patients With High-Grade Gastrointestinal Neuroendocrine Carcinomas
Authors: Angela Lamarca, Thomas Walter, Marianne Pavel, Ivan Borbath, Patricia Freis, Barbara Nuñez, Alexa Childs, Mairéad G. McNamara, Richard A. Hubner, Rocio Garcia-Carbonero, Tim Meyer, Juan W. Valle, Jorge Barriuso
Journal: JNCI Journal of the National Cancer Institute (2016)

Background: Prognostic markers for risk stratification of patients with gastrointestinal high-grade neuroendocrine carcinomas (GI-NECs) are lacking; we designed and validated a prognostic score for overall survival (OS).
RCHOP and RDHAP Followed by Autologous Stem Cell Transplantation (ASCT) in Mantle Cell Lymphoma (MCL) : Final Results of a Phase II Study from the GELA
Authors: Richard Delarue, Corinne Haioun, Vincent Ribrag, Pauline Brice, Alain Delmer, Herve Tilly, Gilles Salles, Achiel Van Hoof, Olivier Casasnovas, Nicole Brousse, Francois Lefrere, Olivier Hermine
Journal: Blood (2008)
Atosiban versus fenoterol as a uterine relaxant for external cephalic version: randomised controlled trial
Authors: Joost Velzel, Floortje Vlemmix, Brent C Opmeer, Jan F M Molkenboer, Corine J Verhoeven, Mariëlle G van Pampus, Dimitri N M Papatsonis, Joke M J Bais, Karlijn C Vollebregt, Liesbeth van der Esch, Joris A M Van der Post, Ben Willem Mol, Marjolein Kok
Journal: BMJ (2017)

<b>Objective</b>&nbsp;To compare the effectiveness of the oxytocin receptor antagonist atosiban with the beta mimetic fenoterol as uterine relaxants in women undergoing external cephalic version (ECV) for breech presentation. <b>Design</b>&nbsp;Multicentre, open label, randomised controlled trial. <b>Setting</b>&nbsp;Eight hospitals in the Netherlands, August 2009 to May 2014. <b>Participants</b>&nbsp;830 women with a singleton fetus in breech presentation and a gestational age of more than 34 weeks were randomly allocated in a 1:1 ratio to either 6.75 mg atosiban (n=416) or 40 μg fenoterol (n=414) intravenously for uterine relaxation before ECV. <b>Main outcome measures</b>&nbsp;The primary outcome measures were a fetus in cephalic position 30 minutes after the procedure and cephalic presentation at delivery. Secondary outcome measures were mode of delivery, incidence of fetal and maternal complications, and drug related adverse events. All analyses were done on an intention-to-treat basis. <b>Results</b>&nbsp;Cephalic position 30 minutes after ECV occurred significantly less in the atosiban group than in the fenoterol group (34% <i>v</i> 40%, relative risk 0.73, 95% confidence interval 0.55 to 0.93). Presentation at birth was cephalic in 35% (n=139) of the atosiban group and 40% (n=166) of the fenoterol group (0.86, 0.72 to 1.03), and caesarean delivery was performed in 60% (n=240) of women in the atosiban group and 55% (n=218) in the fenoterol group (1.09, 0.96 to 1.20). No significant differences were found in neonatal outcomes or drug related adverse events. <b>Conclusions</b>&nbsp;In women undergoing ECV for breech presentation, uterine relaxation with fenoterol increases the rate of cephalic presentation 30 minutes after the procedure. No statistically significant difference was found for cephalic presentation at delivery. <b>Trial registration</b>&nbsp;Dutch Trial Register, NTR 1877.
Platelet Derived Growth Factors in a Mucoadhesive Vehicle for Treatment of Patients with Oral Mucositis in Graft Versus Host Disease
Authors: Claudia Del Fante, Cesare Perotti, Carla Caramella, Cristina Bonferoni, Silvia Rossi, Giuseppina Sandri, Gianluca Viarengo, Laura Salvaneschi
Journal: Blood (2008)
DDIS-07. DEVELOPMENT OF EGFR-TARGETED, DRUG/DYE LOADED NANOSYRINGE FOR SELECTIVE CELLULAR IMAGING
Authors: Martyn Sharpe, David Baskin
Journal: Neuro-Oncology (2016)

Glioblastoma multiforme often has upregulation of extracellular tyrosine kinase receptors such as EGFR and mutant EGFRVIII. This upregulation makes these receptors attractive targets for the binding of drug loaded nanovectors for imaging and patient treatment. We have generated an EGFR-targeted nanosyringe capable of transporting a large drug load to glioma, which undergoes internalization within glioma via the conventional EGF-EGFR coated pit mechanism; PepEGFR-PEG-HCC. The construct is made from an oxidized graphene hydrophobic core functionalized with polyethylene glycol (PEG). Targeting is achieved by ‘clicking’ a EGFR binding peptide on the tips of each PEG, with the peptide identified by phage-display. We have shown that the nanosyringe binds to EGFR, activating the phosphorylation cascade, causing the formation of endosomes via a clathrin mediated endocytosis. This internalization can be halted by EGFR inhibitors such as Erlotinib or by anti-EGFR antibodies. The apparent binding constant for the PepEGFR-PEG-HCC nanosyringe is 20 nM, two orders of magnitude lower than the native peptide, indicating the construct has high avidity. The binding and uptake of the nanosyringe and its drug/dye load is competitive with EGF. High resolution images of U87-EGFR cells exposed to Nile Red-loaded nanosyringes and FITC-labeled EGF show colocalization of both signals. When loaded with the fluorescent chemotherapeutic drug doxorubicin we can observe the real-time binding to gliomal plasma membranes, followed by endosome formation, and then the slow migration of the drug into the nucleus. Intravenous injection of dye loaded nanosyringes into mice with intracranial glioma causes these tumors to take up the nanosyringes and become highly fluorescent. Novel nanosyringes targeting EGFR or other surface epitopes hold great promise for selective cellular imaging of glioblastoma cells. If successful, they may represent a holy grail of imaging, namely selective and imaging of all tumor cells.
Management of subacute airway emergency after blunt neck trauma
Authors: Emily Lowe, Sachin Patil
Journal: BMJ (2017)

A 60 year old woman was admitted after a fall, where she sustained a direct trauma to the anterior neck. She had a progressively worsening hoarse voice, difficulty swallowing, and pain with neck movement. The neck was visibly swollen with bruising tracking onto the anterior chest wall. There was no tenderness on palpation of the cervical spine. A lateral radiograph was taken (fig 1⇓). What does the image show?



Fig 1 

The radiograph shows a massive retropharyngeal haematoma, with distortion of the upper aerodigestive tract and loss of normal cervical lordosis.

### Discussion

A retropharyngeal haematoma can develop after a minor injury but can cause life threatening compromise of the airway. The aetiology …
Cell-Intrinsic Heterogeneity Plays An Important Role in the Development of Clonal Dominance after Retroviral Gene Transfer into Hematopoietic Stem Cells
Authors: Olga S. Kustikova, Bernhard Schiedlmeier, Martijn H. Brugman, Maike Stahlhut, Zhixiong Li, Christopher Baum
Journal: Blood (2008)
Comparison of Insulin Glargine 300 Units/mL and 100 Units/mL in Adults With Type 1 Diabetes: Continuous Glucose Monitoring Profiles and Variability Using Morning or Evening Injections
Authors: Richard M. Bergenstal, Timothy S. Bailey, David Rodbard, Monika Ziemen, Hailing Guo, Isabel Muehlen-Bartmer, Andrew J. Ahmann
Journal: Diabetes Care (2017)

The objective of this study was to compare glucose control in participants with type 1 diabetes receiving insulin glargine 300 units/mL (Gla-300) or glargine 100 units/mL (Gla-100) in the morning or evening, in combination with mealtime insulin.In this 16-week, exploratory, open-label, parallel-group, two-period crossover study (clinicaltrials.gov identifier NCT01658579), 59 adults with type 1 diabetes were randomized (1:1:1:1) to once-daily Gla-300 or Gla-100 given in the morning or evening (with crossover in the injection schedule). The primary efficacy end point was the mean percentage of time in the target glucose range (80-140 mg/dL), as measured using continuous glucose monitoring (CGM), during the last 2 weeks of each 8-week period. Additional end points included other CGM glycemic control parameters, hypoglycemia (per self-monitored plasma glucose [SMPG]), and adverse events.The percentage of time within the target glucose range was comparable between the Gla-300 and Gla-100 groups. There was significantly less increase in CGM-based glucose during the last 4 h of the 24-h injection interval for Gla-300 compared with Gla-100 (least squares mean difference -14.7 mg/dL [95% CI -26.9 to -2.5]; P = 0.0192). Mean 24-h glucose curves for the Gla-300 group were smoother (lower glycemic excursions), irrespective of morning or evening injection. Four metrics of intrasubject interstitial glucose variability showed no difference between Gla-300 and Gla-100. Nocturnal confirmed (<54 mg/dL by SMPG) or severe hypoglycemia rate was lower for Gla-300 participants than for Gla-100 participants (4.0 vs. 9.0 events per participant-year; rate ratio 0.45 [95% CI 0.24-0.82]).Less increase in CGM-based glucose levels in the last 4 h of the 24-h injection interval, smoother average 24-h glucose profiles irrespective of injection time, and reduced nocturnal hypoglycemia were observed with Gla-300 versus Gla-100.
Potential Hypoxic Renal Injury in Patients With Diabetes on SGLT2 Inhibitors: Caution Regarding Concomitant Use of NSAIDs and Iodinated Contrast Media
Authors: Samuel N. Heyman, Mogher Khamaisi, Seymour Rosen, Christian Rosenberger, Zaid Abassi
Journal: Diabetes Care (2017)

In their seminal work, Wanner et al. (1) found that the sodium–glucose cotransporter 2 (SGLT2) inhibitor empagliflozin provided renal protection over 4 years of follow-up in patients with type 2 diabetes. Furthermore, the incidence of overt acute kidney injury (AKI) showed a trend in favor of the treatment group, especially beyond 18 months of randomization. However, a recent U.S. Food and Drug Administration Drug Safety Communication reports 101 cases of AKI in patients treated with SGLT2 inhibitors, some of whom required hospitalization and dialysis (2).

There might be a few explanations for this troubling news, other than mere chance and publication bias. While an initial reduction in glomerular filtration rate, related to transglomerular pressure reduction, is a reversible inherent factor of long-term renal protection, SGLT2 inhibition could potentially …
Autologous Stem Cell Transplantation (ASCT) Versus Oral Melphalan and High-Dose Dexamethasone In Patients with AL (Primary) Amyloidosis: Long Term Follow-up of the French Multicentric Randomized Trial
Authors: Arnaud Jaccard, Veronique Leblond, Bruno Royer, Xavier Leleu, Richard Delarue, Brigitte Kolb, Eric Deconinck, Aspasia Stamatoullas, Paul Coppo, Bertrand Arnulf, Olivier Hermine, Philippe Moreau, Jean Paul Fermand
Journal: Blood (2010)
An Edible, High Molecular Weight Glycoprotein Fraction from Ganoderma Lucidum Inhibits the Akt Pathway in Resistant Myeloma Cell Lines Decreasing Mcl-1 Expression, Up-Regulating FKHR and Inducing Apoptosis.
Authors: Nazneen Sultana, Larissa Verda, Richard K. Burt, Ann E. Traynor
Journal: Blood (2004)
Possible Involvement of Heparin-Binding Protein in Antibody-Mediated Non-Hemolytic Transfusion Reaction.
Authors: Rika A. Furuta, Kazuta Yasui, Nobuki Matsuyama, Yasuo Fukumori, Takafumi Kimura, Fumiya Hirayama, Yoshihiko Tani, Hirotoshi Shibata
Journal: Blood (2007)
Elotuzumab In Combination with Lenalidomide and Dexamethasone In Patients with Relapsed Multiple Myeloma: Interim Results of a Phase 2 Study
Authors: Paul G. Richardson, Philippe Moreau, Andrzej J Jakubowiak, Thierry Facon, Sundar Jagannath, Ravi Vij, Donna E Reece, Darrell J White, Marc S Raab, Lotfi Benboubker, Jean-Francois Rossi, Claire Tsao, John Fry, David Berman, Anil K Singhal, Sagar Lonial
Journal: Blood (2010)
Ercc1 Mrna Expression and Kras Mutation Status In Egfr Wild Type (wt) Advanced Non-small Cell Lung Cancer (nsclc) Patients
Authors: G Metro, M Cenci, A Siggillino, R Chiari, Fr Tofanetti, D Giannarelli, L Pistola, A Flacco, G Bennati, G Bellezza, S Baglivo, A Sidoni, Ludovini, L Crinò
Journal: Journal of Thoracic Oncology (2013)
Monoclonal Gammopathy of Undertermined Significance (MGUS): Clinical Predictors of Malignant Transformation in 434 Patients with a Long Follow-Up from a Single Institution.
Authors: L. Rosiñol, S. Montoto, J. Bladé, M.T. Cibeira, M. Rozman, E. Nadal, E. Giné, M. Aymerich, J. Esteve, E. Montserrat
Journal: Blood (2004)
Effects of EGF-R on Signal Transduction and Anti-Apoptotic Cascades in Hematopoietic Cells: EGF-R Activates Multiple Signal Transduction Cascades Which Result in the Prevention of Apoptosis in the Absence of Autocrine Cytokines.
Authors: John G. Shelton, Linda S. Steelman, Martin McMahon, James A. McCubrey
Journal: Blood (2004)
Antipruritic effect of pretreatment with topical capsaicin 8% on histamine- and cowhage-evoked itch in healthy volunteers: a randomized, vehicle-controlled, proof-of-concept trial
Authors: H.H. Andersen, J.B. Marker, E.A. Hoeck, J. Elberling, L. Arendt-Nielsen
Journal: British Journal of Dermatology (2017)

Chronic itch is difficult to treat. Low‐concentration topical capsaicin (0·006–0·05%) has previously been applied in itch therapy but evidence on its efficacy is contradictory. This vehicle‐controlled, double‐blinded study investigated the effect of topical capsaicin 8% after 1‐ and 24‐h application on evoked itch, neurogenic inflammation and itch‐associated dysaesthesia. Sixteen healthy volunteers (aged 22 ± 0·5 years, nine female) were treated with capsaicin for 1 h and 24 h, and vehicle for 24 h on each volar forearm. Subsequently, histamine (1%, administered prick test lancets) and cowhage (40–45 spicules) were applied to the pretreated areas. Evoked itch and pain intensities were recorded for 10 min using a visual analogue scale (0–10 cm), while sensitivity to touch‐evoked itch was evaluated using von Frey filaments before and after itch provocations. Neurogenic inflammation was assessed using perfusion imaging. In the vehicle areas peak itch responses to histamine and cowhage were 4·67 ± 0·58 and 5·15 ± 0·71, respectively. Capsaicin pretreatment reduced peak itch responses to histamine and cowhage after 24‐h pretreatment to 1·41 ± 0·58 (P = 0·003) and 0·81 ± 0·18, (P < 0·001), respectively. Capsaicin pretreatment for 1 h reduced only cowhage‐induced itch (P = 0·023). Furthermore, 24‐h capsaicin pretreatment abolished punctuate hyperknesis and lowered histamine‐induced neurogenic inflammation but did not affect weal reactions. Topical capsaicin 8% pretreatment for 24 h reduced histaminergic and nonhistaminergic itch by about 75%, while a significant reduction (≈60%) was achieved for only nonhistaminergic itch in a standard 1‐h treatment. Further investigations are needed to elucidate the clinical potential of high‐concentration capsaicin as an antipruritic.
Resveratrol Plus Simvastatin Are Effective in Decreasing IgM Secretion in Asymptomatic Waldenstrom Macroglobulinemia. One Year Follow-up.
Authors: Francesco Iuliano, Stefania Infusino, Alessia Perricelli, Massimo Di Maio, Angelo Pomillo, Maria Luci, Francesco Mingrone
Journal: Blood (2009)